pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Lead Candidate · news · pharmadog
← back to Lead Candidate
News mentioning Lead Candidate
42
stories
1d
Kolon TissueGene cuts 37 US staffers after Phase 3 fail
biospace
2d
BioMarin acquires experimental drug for rare bone disorder in $275M deal
biopharma dive
3d
EyePoint plummets on pivotal data for main drug
biopharma dive
4d
Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trials
fiercebiotech
6d
Abcuro gets $66M for Phase 3 in muscle-weakening condition
endpoints
6d
MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlonta
endpoints
6d
Skye and Redx form new entity with $125M to advance fibrosis assets
fiercebiotech
8d
Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pill
fiercebiotech
9d
After slimming down workforce, Aardvark scraps phase 3 trials as wait for next steps drags on
fiercebiotech
9d
Epicrispr, Infinimmune snag combined $165M in VC cash
biospace
10d
Aura lays off 20% of workforce, rejigs C-suite amid R&D refocus on eye cancer
fiercebiotech
10d
Regeneron backs $75M series A for antibody upstart Infinimmune
fiercebiotech
10d
Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline
biospace
10d
ITM neuroendocrine tumor drug spurned by FDA over manufacturing qualms
fiercebiotech
11d
Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapies
fiercebiotech
13d
BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
fiercebiotech
14d
Braveheart pumps more life into biotech IPO market with $382M expected debut
biospace
14d
Tarsus bets $450M on Alkeus’ Stargardt drug
endpoints
14d
LifeMine raises $263M in mission to improve organ transplant aftercare
biospace
14d
Vedanta gets $60M to finish Phase 3 for C. diff microbiome therapy
endpoints
14d
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
globenewswire health
14d
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
globenewswire health
16d
Lilly drops another gene therapy trial from $1B Prevail buyout
fiercebiotech
16d
5 NextGen winners who went public this year (and which ones are hiring)
biospace
16d
Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO
fiercebiotech
18d
BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger
fiercebiotech
20d
Capricor CEO won’t rule out legal action against FDA after negative adcomm
biospace
21d
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
fiercebiotech
21d
Chutes & Ladders—Legend CEO departs without successor in place
fiercebiotech
23d
‘Reverse mergers are increasingly popular’: Caldera hops on Synlogic’s Nasdaq listing
fiercebiotech
← prev
page 1 of 2
next →
